Dasatinib vs Navitoclax
Written by Aaron CuhaReviewed Sep 2026
The short answer
The two prescription senolytics that real people have taken, coming from opposite directions. Navitoclax is the most cited senolytic in mice and cannot be given to healthy people. In its first human trial, 29 of 55 patients with blood cancers had a severe drop in platelets, the cells that help blood clot.
- Dasatinib people
- 74
- Dasatinib nulls
- 1
- Navitoclax people
- 137
- Navitoclax nulls
- 0
Dose
Approved medicine. No human dose established for unlabelled uses
Labeled amounts sit on the prescribing information. This page records what trials measured, not a personal dose.
FDA-approved for leukemia; using it to clear out worn-out cells is off-label and investigational
Dose
No human dose established
Amounts that were given in studies sit in Human evidence on this page. None of them is a personal dose.
2 completed trials, 137 people given it
First-hand reports are counted on each profile and never added together. This page sets two published records side by side. It does not pick a winner.
Column A
DasatinibDasatinib (senolytic; approved leukemia drug)
An approved leukemia drug also tried, with quercetin, to clear worn-out cells. Early studies with no comparison group looked good. The proper studies that followed did not.
Column B
NavitoclaxNavitoclax (ABT-263), oral BCL-2, BCL-xL and BCL-w inhibitor
The most-quoted drug for clearing worn-out cells in mice, and the one you cannot give to healthy people. In its first study in people, 29 of 55 cancer patients saw their platelets, the blood cells that stop bleeding, drop to dangerous levels. Platelets stay alive using the same protein the drug blocks.
Side by side, on the facts we can check
| What we compare | Dasatinib | Navitoclax |
|---|---|---|
| Category | Longevity | Longevity |
| FDA status | FDA-approved for leukemia; using it to clear out worn-out cells is off-label and investigational | Not approved for any use, in any country. It has been tested as a cancer drug since 2006. No study for ageing or for clearing worn-out cells is registered on ClinicalTrials.gov. |
| Half-life | ~3-5 hours | Not reported |
| Molecular weight | 488.0 Da | Not reported |
| How it works | It blocks survival signals inside worn-out cells, so they die. It works best alongside quercetin. | Shown in human cells and in mice: navitoclax sits in a pocket on BCL-2, BCL-xL and BCL-w. That frees up other proteins that tell the cell to die, so cells that lean on those three proteins die off. In mice, worn-out cells lean on them, which is why the drug hits those cells hardest. In people, platelets lean on the same protein, so their count drops. The cancer studies confirmed that. The clean-up effect seen in mice has never been shown in a person. |
| Studies in people | 4 | 4 |
| Evidence | Limited: 3 completed trials, 74 people given it | Moderate: 2 completed trials, 137 people given it |
| Legal status, US | FDA-approved (for its labeled use), prescription only | Investigational, not approved |
Frequently asked questions
What is the difference between Dasatinib and Navitoclax?
Dasatinib: An approved leukemia drug also tried, with quercetin, to clear worn-out cells. Early studies with no comparison group looked good. The proper studies that followed did not. Navitoclax: The most-quoted drug for clearing worn-out cells in mice, and the one you cannot give to healthy people. In its first study in people, 29 of 55 cancer patients saw their platelets, the blood cells that stop bleeding, drop to dangerous levels. Platelets stay alive using the same protein the drug blocks.
Which has stronger research evidence, Dasatinib or Navitoclax?
Each compound gets a band worked out from facts we counted, with the math shown. Dasatinib is Limited (3 completed trials, 74 people given it). Navitoclax is Moderate (2 completed trials, 137 people given it). That counts how much has been done in people. It does not rate whether either one works, and neither one is called the winner.
Are Dasatinib and Navitoclax FDA-approved?
Dasatinib: FDA-approved for leukemia; using it to clear out worn-out cells is off-label and investigational. Navitoclax: Not approved for any use, in any country. It has been tested as a cancer drug since 2006. No study for ageing or for clearing worn-out cells is registered on ClinicalTrials.gov..
Related posts
Blog articles that cover Dasatinib or Navitoclax, newest first.
- Longevity / Sep 27, 2026 / 12 minPeptides for Longevity: What the Evidence Actually Shows in 2026
- Longevity / Sep 27, 2026 / 9 minSenolytics in 2026: Dasatinib plus Quercetin, Fisetin, and What Human Trials Have Shown
- Longevity / Sep 27, 2026 / 9 minThe Rapamycin Dosing Debate: What PEARL Tested, the Bioavailability Problem, and What Is Unproven
- Longevity / Sep 27, 2026 / 8 minKlotho Explained: Protein, Peptide, Gene Therapy or Supplement?
Reviewed Sep 2026. This page puts two published records side by side. It is for learning, and it is not medical advice. When this site shows a dose, it is the dose a trial or a clinic actually used, or what people say they did, with the source attached. None of it tells you what to take.